April 2014, 22:9

03 December 2014

Original Paper

Original Paper

Aspirin for prophylaxis of venous thromboembolism

Chloe Ting, Leonardo P. de Carvalho, Mark Y. Chan 

ASEAN Heart Journal

First online: 

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon

Reference Tools



Cessation of vitamin K antagonists (VKA) after a primary incidence of spontaneous venous thromboembolism (VTE) has been associated with recurrent events in about one-fifth of patients. Although long-term continuation of VKA prophylaxis has been suggested as a means to prevent recurrent VTE, concerns remain over issues of high bleeding risk, patient non-compliance as well as dosage irregularities. Antiplatelet therapy has been proposed as a safer, cheaper and more convenient alternative for long-term prophylaxis after initial treatment with VKA following VTE. Here we compare two major randomized trials that were conducted back-to-back – the WARFASA trial and the ASPIRE trial – to determine the role of aspirin as a long-term treatment option to reduce the incidence of recurrent VTE. Despite the encouraging results of these trials, suggesting that aspirin may have a beneficial effect on secondary prevention of VTE, it must be emphasized that both trials only started aspirin after 6-18 months of treatment with VKA, which remain a cornerstone of management for a first unprovoked VTE.



Aspirin - Antiplatelet Therapy - High Bleeding Risk - Aspire Study - Aspire Trial





1 Yong Loo-Lin School of Medicine, National University of Singapore

2 National University Heart Centre, Singapore

Correspondence to Mark Y. Chan, Associate Professor

Yong Loo-Lin School of Medicine, National University of Singapore

1E, Kent Ridge Road, NUHS Tower Block, Level 9, Cardiac Department, Singapore 119228

Tel: +65 67725596 Fax: +65 68722998

Email: mark_chan@nuhs.edu.sg

Open Access: This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.


Tel No: +603-7931 7900
Fax No: +603-7932 1400



D-13A-06, Menara Suezcap 1, KL Gateway,
No.2 Jalan Kerinchi, Gerbang Kerinchi Lestari,
59200 Kuala Lumpur, Malaysia.


ASEAN HEART Journal is Supported by Unrestricted Grant From 

Committed to therapeutic advances in cardiovascular research